In a report released today, David Turkaly from JMP Securities maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price target of $145.00. The company’s shares closed yesterday at $128.52.
According to TipRanks, Turkaly is a 4-star analyst with an average return of 5.1% and a 50.21% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Paragon 28, Steris, and Apyx Medical.
In addition to JMP Securities, Zimmer Biomet Holdings also received a Buy from Robert W. Baird’s Jeff Johnson in a report issued yesterday. However, on the same day, Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (NYSE: ZBH).
See the top stocks recommended by analysts >>
Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $1.67 billion and a net profit of $194 million. In comparison, last year the company earned a revenue of $1.69 billion and had a net profit of $145.6 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.
Read More on ZBH:
- Zimmer Biomet price target raised to $135 from $130 at Piper Sandler
- Zimmer Biomet sees FY23 adjusted EPS $6.95-$7.15, consensus $6.98
- Zimmer Biomet reports Q4 EPS $1.88, consensus $1.83
- Zimmer Biomet Announces Fourth Quarter and Full-Year 2022 Financial Results
- Increasing Medical Issues Bode Well for Zimmer Biomet Stock (NYSE:ZBH)